key: cord-0912314-zkdk2v5e
authors: Cheng, Xu; Liu, Ye-Mao; Li, Haomiao; Zhang, Xin; Lei, Fang; Qin, Juan-Juan; Chen, Ze; Deng, Ke-Qiong; Lin, Lijin; Chen, Ming-Ming; Song, Xiaohui; Xia, Meng; Huang, Xuewei; Liu, Weifang; Cai, Jingjing; Zhang, Xiao-Jing; Zhou, Feng; Zhang, Peng; Wang, Yibin; Ma, Xinliang; Xu, Qingbo; Yang, Juan; Ye, Ping; Mao, Weiming; Huang, Xiaodong; Xia, Jiahong; Zhang, Bing-Hong; Guo, Jiao; Zhu, Lihua; Lu, Zhibing; Yuan, Yufeng; Wei, Xiang; She, Zhi-Gang; Ji, Yan-Xiao; Li, Hongliang
title: Metformin Use Is Associated with Increased Incidence of Acidosis but not Mortality in Individuals with COVID-19 and Pre-existing Type 2 Diabetes
date: 2020-08-20
journal: Cell Metab
DOI: 10.1016/j.cmet.2020.08.013
sha: 34641fb9ded209132911fab119ffec92c86a0a9a
doc_id: 912314
cord_uid: zkdk2v5e

Summary The safety and efficacy of anti-diabetic drugs are critical for maximizing the benefical impacts of well-controlled blood glucose on the prognosis of individuals with COVID-19 and pre-existing type 2 diabetes (T2D). Metformin is the most commonly prescribed first-line medication for T2D, but its impact on the outcomes of individuals with COVID-19 and T2D remains to be clarified. Our current retrospective study in a cohort of 1,213 hospitalized individuals with COVID-19 and pre-existing T2D indicated that metformin use was significantly associated with a higher incidence of acidosis, particularly in cases with severe COVID-19, but not with 28-day COVID-19-related mortality. Furthermore, metformin use was significantly associated with reduced heart failure and inflammation. Our findings provide clinical evidence in support of continuing metformin treatment in individuals with COVID-19 and pre-existing T2D, but acidosis and kidney function should be carefully monitored in individuals with severe COVID-19.

The spread of the severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) infection is unprecedented in its global scale and speed, afflicting more than 20.4 million people with the novel coronavirus disease , resulting in more than 744,000 deaths globally as of August 13, 2020 . Accumulating evidence has demonstrated that diabetes mellitus, particularly type 2 diabetes (T2D), is a major comorbidity that significantly increases the risk of death and adverse complications in individuals with COVID-19 (Richardson et al., 2020; Zhu et al., 2020) . We recently found, in one of the largest retrospective cohort studies of in-hospital individuals, that well-controlled blood glucose is associated with a remarkable reduction of death and adverse complications in individuals with COVID-19 and pre-existing T2D , indicating the importance and likely the necessity of intensive blood glucose management in these individuals.

Metformin is a leading first-line anti-diabetic medication (American Diabetes Association (2019), 2019). It is the most commonly prescribed drug for the treatment of T2D (used by 30%-88% individuals with T2D), owing to its low cost, good safety profile and a broad spectrum of clinical benefits (Bailey, 2017; Overbeek et al., 2017; Zhu et al., 2020) . For individuals with COVID-19 and pre-existing T2D, the established beneficial effects of metformin on blood glucose management (Foretz et al., 2014) , cardiac protection (Foretz et al., 2014) and immune-modulation (Ursini et al., 2018 ) may result in a more beneficial outcome of the viral disease than if metformin use is withheld.

However, concerns have been raised regarding the potential side effects of metformin use as it can promote lactic acidosis in individuals with COVID-19 and pre-existing T2D, particularly for individuals with severe symptoms of COVID-19 (Bornstein et al., 2020) . In addition, the potential of metformin to enhance the expression of angiotensin-converting enzyme 2 (ACE2) (Zhang et al., 2018a) , the viral receptor for SARS-COV-2 (Hoffmann et al., 2020) , has also raised the concern that metformin use may promote the progression of COVID-19. Hence, whether metformin use should be recommended or discontinued in individuals with COVID-19 and pre-existing T2D still remains highly controversial. Considering the urgency of the COVID-19 pandemic, and the significant number of individuals with COVID-19 and pre-existing T2D who could be treated by metformin, information on the clinical impact of its usage in the context of COVID-19 would have significant and immediate implications.

In this study, we retrospectively enrolled 15,451 confirmed COVID-19 cases that were admitted among 16 hospitals from Hubei Province, China, among which 2,563 individuals had pre-existing T2D, to investigate the relationship between in-hospital use of metformin and the clinical outcomes in those individuals with COVID-19 and pre-existing T2D. Our findings indicate that metformin use is associated with increased incidence of acidosis but not 28-day all-cause mortality in individuals J o u r n a l P r e -p r o o f with COVID-19 and pre-existing T2D. Furthermore, metformin use was significantly associated with reduced heart failure as well as an inflammatory response. These findings offer important information to assist clinicians in the decision to use metformin to manage diabetes in individuals with J o u r n a l P r e -p r o o f

A total of 2,563 individuals with confirmed COVID-19 and with T2D from 16 hospitals in Hubei Province, China were initially included for this study. A total of 184 individuals younger than 18 or older than 80 years, 133 without complete medical records, 16 with pregnancy, 6 with acute myocardial infarction, 1 with acute stroke, 4 with severe acute pancreatitis, and 7 with cirrhosis were excluded. The individuals with contraindications for taking metformin, including 106 with an estimated glomerular filtration rate (eGFR) < 30 ml/min/1.73 m 2 (i.e., greater than stage 4 renal insufficiency), 4 with prehospital ketoacidosis, and 2 with prehospital hyperosmolar coma were excluded. We also excluded 550 individuals without any anti-diabetic treatment and 337 individuals using insulin as the only anti-diabetic medication (Figure 1 ).

The final cohort had 1,213 individuals with T2D, including 678 subjects (male, 53.8 %) treated with metformin or metformin plus other anti-diabetic drugs (referred to as the metformin group) and 535 individuals (male, 49.9 %) treated with anti-diabetic drugs other than metformin (referred to as the non-metformin group). The baseline characteristics on admission for both groups are shown in Table 1 . The median ages were 62 (IQR, 55-68) and 64 (IQR, (58) (59) (60) (61) (62) (63) (64) (65) (66) (67) (68) (69) (70) years in the metformin and the non-metformin groups, respectively. The median body mass index (BMI) was 24.3 (IQR, vs. 24.5 (IQR, 2) kg/m 2 in the metformin versus the non-metformin groups, respectively.

While individuals in both groups exhibited similar levels of elevated systolic blood pressure (SBP), the metformin group had lower incidences of pre-existing coronary heart disease (12.4% vs. 17.9%) and cerebrovascular disease (2.5% vs. 5.2%) than the non-metformin group. The proportion of individuals with increased C-reactive protein (CRP) levels in the metformin group were lower than that in the non-metformin group (46.9% vs. 55.7%). The median fasting glucose level was higher in the metformin group (9.0, IQR, 6.7-13.1) compared to that in the non-metformin group (8.3, IQR, 6.4-11.8 mmol/L). Meanwhile, the percentage of HbA1c in the metformin group (8.1, IQR, 7.0-9.9%) was also higher than that in the non-metformin group (7.6, IQR, 6.7-8.9%). Chest computerized tomography (CT) scan and major lab examinations results were similar or marginally different between the two groups. There were similar numbers of cases with severe COVID-19 in the metformin group versus the non-metformin group (32.60% vs. 33.83%, P = 0.695) on admission.

J o u r n a l P r e -p r o o f Metformin lowers glucose levels mainly by reducing hepatic glucose production through inhibiting the mitochondrial respiratory chain, preventing intestinal glucose absorption, as well as enhancing glucose uptake and utilization by peripheral tissues (Foretz et al., 2014) . The blockage of oxidative phosphorylation also promotes anaerobic metabolism, which increases the risk of accumulation of the by-product lactate (Rena et al., 2017) . Metformin-induced lactic acidosis was first reported when 66 individuals treated with metformin developed lactic acidosis within one year after metformin was introduced in the United States (Misbin et al., 1998) . The actual incidence of lactic acidosis is approximately 1 in 23,000 to 30,000 person per year among metformin users (Bodmer et al., 2008; Inzucchi et al., 2014) . However, in the setting of infection and sepsis hyperlactatemia can be dramatically induced mainly due to inadequate oxygen delivery, leading to tissue hypoxia and enhanced anaerobic glycolysis (Suetrong and Walley, 2016) . Elevated serum lactate is associated with increased mortality, independent of organ failure and shock (Bakker et al., 1991; Mikkelsen et al., 2009) .

In this study, we first investigated the well-known lactic acidosis-promoting effect of metformin.

In the metformin group, 20 individuals (2.95%) developed acidosis and 12 individuals (1.77%) developed lactic acidosis, percentages that are higher compared to those of the non-metformin group (1.5% acidosis and 0.75% lactic acidosis, respectively). As metformin use could be dynamically determined by the medication status during hospitalization, the Cox regression model with time-varying exposure was applied to the entire cohort to analyze the association between metformin use and the incidence of acidosis, in which daily use of metformin was considered as a covariable.

Here, the adjusted variables for comparison between metformin and non-metformin groups included age, gender, comorbidities (cerebrovascular disease and coronary heart disease), blood glucose, CRP elevation, eGFR, alanine aminotransferase (ALT) elevation and creatinine elevation. In this model, the risks for both lactic acidosis (adjusted HR, 4.66; 95% CI, ; P = 0.010) and acidosis (adjusted HR, 2.45; 95% CI, 1.08-5.54; P = 0.032) were significantly higher in the metformin group than that in the non-metformin group ( Table 2) . To validate the statistical model, Schoenfeld's global test was performed. The P-values in all models were greater than 0.05, which indicated that the time-varying Cox models were consistent and fit for evaluating acidosis and lactic acidosis in this study ( Table S1) . The E-values for acidosis and lactic acidosis are 4.33 and 8.79, respectively.

To verify the robustness of the model, two sensitivity analyses were performed. First, we performed identical analysis after the subjects from one of the participating hospitals was randomly removed, the adjusted HR from this new cohort for lactic acidosis was 4.53 (95% CI, 1.41-14.59; P = 0.011), and the adjusted HR for acidosis was 2.59 (95% CI, 1.04-6.47; P = 0.042). In the second sensitivity analysis, we randomly removed the data from another participating hospital before analysis, and the higher risk of lactic acidosis (adjusted HR, 4.71; 95% CI, 1.46-15.17; P = 0.009) and acidosis (adjusted HR, 2.50; 95% CI, 1.10-5.67; P = 0.029) were maintained in the metformin group versus the non-metformin group.

Kernel density measurements across the entire cohort or the sub-groups in each cohort based on the severity of COVID-19 (mild and severe) were performed using Gaussian kernels and showed that there were remarkably more individuals who had a higher level of lactic acid as well as a lower blood pH among the metformin users than that in the non-metformin users, particularly in individuals with severe COVID-19 ( Figure S1 ).

To further evaluate this effect based on a similar baseline status between the two groups at admission, we conducted a propensity score-matching (PSM) analysis. In this model, the imbalanced baseline characters, including age, sex, major comorbidities (hypertension, coronary artery disease, cerebrovascular disease, chronic liver disease, chronic kidney disease and heart failure on admission), fever and dyspnea, vital signs (heart rate, breath and blood pressure), oxygen saturation (SpO2) < 95, CT lesion, increase of neutrophils, blood glucose, increase of CRP, decrease of lymphocytes, kidney function (i.e., eGFR), proportion of insulin usage, indicators of liver injury (i.e., elevation of ALT) and heart injury (i.e., elevation of cardiac troponinI [cTNI]), were firstly balanced by PSM. In the matched cohorts (468 individuals in each group, Table S2 ), individuals in the metformin group and the non-metformin group received comparable treatments except for the fewer incidence of antithrombotic or thrombolysis use in the metformin group (Table S3) . Following mixed-effect Cox model analysis, after adjusted for age, gender, increase of CRP, Aspartate transaminase (AST), urea, and creatinine, decrease of red blood cell (RBC) and hospital site (random effect), the results also indicated that the metformin users had a higher risk of developing lactic acidosis (adjusted HR, 4.46; 95% CI, 1.11-18.00; P = 0.036) and acidosis (adjusted HR, 2.73; 95% CI, 1.04-7.13; P = 0.040) ( Table 2 ). Harrell's concordance indexes (C-indexes) were calculated to evaluate the prediction capability of the mixed-effect Cox model. The results indicated that the mixed-effect Cox model was fit for predicting the association between metfromin use and acidosis in this study (Table S4) . Taken together, these two models consistently demonstrated that metformin use was significantly associated with increased incidences of developing lactic acidosis and acidosis in individuals with COVID-19 and pre-existing T2D.

We further analyzed the factors associated with the development of lactic acidosis and acidosis in individuals with COVID-19 and pre-existing T2D by using binary logistic regression model analysis ( Table 3 ). The candidate factors included age, sex, the dosage of metformin, eGFR, comorbidities on admission and baseline characteristics. The results indicated that metformin use at 2 ≤ Dose < 3 g/day was significantly associated with an increased incidence of developing lactic acidosis (OR, J o u r n a l P r e -p r o o f 22.57; 95% CI, 1.99-256.71; P = 0.012) and acidosis (OR, 12.79; 95% CI, 1.24-132.14; P = 0.032), while neither low-dose (< 1 g/day) nor moderate-dose (1 ≤ Dose < 2 g/day) metformin use was significantly associated with the acidosis and lactic acidosis. Furthermore, insufficient kidney function, particularly eGRF < 60ml/min/1.73m 2 , was also associated with a higher risk of developing lactic acidosis (OR, 3.94; 95% CI, 1.05-14.76; P = 0.042) and acidosis (OR, 5.21; 95% CI, 1.83-14.81; P=0.002). Further subgroup analysis in individuals with an eGFR >60 ml/min/1.73 m 2 indicated that the incidences of acidosis were similar between metformin and non-metformin groups (Table S5 ). These results indicated that metformin use was not associated with acidosis in individuals with better renal function. We also noticed that the percentage of individuals with impaired renal function in the metformin group was significantly lower than that in the non-metformin group (7.82% vs. 11.78%, P = 0.026). The indicators for the severity of COVID-19, including SpO2 < 93 (National Health Commission of China 2020; World Health Organization, 2020; Zhang et al., 2020) and neutrophil-to-lymphocyte ratio (NLR) > 3.13 , were also found to be associated with the onset of lactic acidosis and acidosis in individuals with COVID-19 and pre-existing T2D. Further investigation indicated that no acidosis associated with metformin use was found in individuals with non-severe COVID-19 (Table S6) . Taken together, these findings suggest that using metformin in individuals with severe COVID-19 should be accompanied by carefully monitoring of acidosis and kidney function.

Next, we investigated whether higher incidences of developing lactic acidosis and acidosis in the metformin group would translate into worse adverse outcomes in individuals with COVID-19 and pre-existing T2D. We firstly noticed that there was no difference between the durations of hospitalization in the metformin and the non-metformin users (21 days vs. 21 days, P = 0.687), although individuals with acidosis did have non-significantly longer hospitalization than those without acidosis (26 days vs. 21 days, P = 0.213). In the Cox regression model with time-varying exposure, there was no significant difference in the mortalities of individuals between the metformin and the non-metformin groups (adjusted HR, 0.87; 95% CI, 0.36-2.12; P = 0.757) ( Table 4) . Notably, comorbidities as well as other potential covariables, including blood glucose, at hospital admission were adjusted in the analysis. Meanwhile, secondary endpoints, including acute respiratory distress syndrome (ARDS), disseminated intravascular coagulation (DIC), heart failure, acute kidney injury and acute heart injury, were also analyzed. We found that the incidence of heart failure was significantly lower in the metformin group compared to the non-metformin group (adjusted HR, 0.61; 95% CI, 0.43-0.87; P = 0.006) ( Table 4 ). The incidence of ARDS was also significantly lower in the metformin group compared to the non-metformin groups (adjusted HR, 0.66; 95% CI, 0.46-0.96; P = 0.028) ( Table 4) . Notably, Schoenfeld's global test validated that the time-varying Cox models were J o u r n a l P r e -p r o o f consistent and fit for evaluating the outcomes in this study (Table S1 ).In this model, we also calculated the joint effect of metformin use on acute extra-pulmonary organ injury, including acute heart injury, acute kidney injury and DIC. Consistent with the results calculated separately, metformin use was not associated with the outcome of acute extra-pulmonary organ injury (Table S7) .

To further validate these findings, a mixed-effect Cox model analysis following PSM analysis after balancing baseline clinical characteristics (including blood glucose) was applied. Again, this model found comparable mortalities between the metformin and the non-metformin groups (adjusted HR, 1.65; 95% CI, 0.71-3.86; P = 0.247), but revealed significantly lower incidence of heart failure in the metformin group (adjusted HR, 0.59; 95% CI, 0.41-0.83; P = 0.003) compared to non-metformin group ( Table 4) , which was confirmed by sensitivity analyses. The validity of this model in predicting the association between metformin use and outcomes was also refleted by calculating C-indexes (Table s4) . Altogether, these findings indicated that metformin use was not associated with increased mortality but with decreased incidence of developing heart failure in individuals with COVID-19 and pre-existing T2D.

This finding is in agreement with a Korean population-based cohort study, which also showed no significant association was indicated between metformin therapy and 30-day mortality in individuals with ARDS and pre-existing diabetes (Oh and Song, 2020) . In an earlier study in a cohort from Israel consisting of individuals diagnosed with septic shock and severe lactic acidosis, the mortality rate was significantly lower in those receiving metformin treatment (Doenyas-Barak et al., 2016) . One recent retrospective study with a limited number of cases (n = 283) also showed that metformin treatment was associated with decreased mortality in individuals with COVID-19 and diabetes, although without excluding individuals who received only insulin as a glucose-lowering agent in the non-metformin group the conclusions may have been biased (Luo et al., 2020) .

Diabetic individuals with a different severity of COVID-19 may have a different reaction to metformin treatment. To further delineate the effect of metformin use on developing acidosis, mortality and acute organ injuries, individuals with COVID-19 and pre-existing T2D were analyzed in subgroups according to the severity of COVID-19 symptoms at baseline. The baseline characteristics for the mild and the severe COVID-19 subgroups are shown in Table S8 . In individuals with mild COVID-19, there were no cases of lactic acidosis and acidosis reported in either the metformin group or the non-metformin group. In individuals with severe COVID-19, the Cox regression model with time-varying exposure indicated that the incidences of both lactic J o u r n a l P r e -p r o o f acidosis (adjusted HR, 4.97; 95% CI, 1.66-14.92; P = 0.004) and acidosis (adjusted HR, 2.67; 95% CI, 1.20-5.94; P = 0.016) were significantly higher in the metformin group than that in the non-metformin group (Table S9) . These findings were further evaluated by balancing the baseline characteristics using PSM (Table S9) in both mild and severe groups. The characteristics and treatment records for the mild and the severe COVID-19 subgroups after PSM are shown in Table   S10 and Table S11 , respectively. The following mixed-effect Cox model analysis also indicated that the metformin users had a higher risk of developing lactic acidosis (adjusted HR, 5.65; 95% CI, 1.06-30.10; P = 0.042) and acidosis (adjusted HR, 3.82; 95% CI, 1.27,11.50; P=0.017) in individuals with severe COVID-19 (Table S9) . While no patient with mild COVID-19 died during the 28-day observation, the degree of mortality of individuals with diabetes and severe COVID-19 were comparable between the metformin and non-metformin groups using either the Cox regression model with time-varying exposure or mixed-effect Cox model following PSM analysis (Table S9) . Notably, the lower incidence of heart failure was consistently observed in the metformin group compared to the non-metformin group by either statistical approaches (Table S9 ). These results suggest that the acidosis-promoting effect of metformin may have been compensated by its protective effects in the heart (Foretz et al., 2014; Ursini et al., 2018) in individuals with COVID-19 and pre-existing T2D, even in severe COVID-19 cases.

The above analysis demonstrated that metformin use was associated with an increased incidence of developing acidosis but not mortality in individuals with COVID-19 and pre-existing T2D, particularly in individuals with severe COVID-19 symptoms. Accumulating evidence indicates that many individuals with severe COVID-19 exhibit cytokine storm syndrome. Therefore, it has been proposed to identify and test currently approved therapies with proven safety profiles to reduce hyper inflammation in COVID-19 (Mehta et al., 2020) . Metformin was originally derived from Galega officinalis and is believed to have bacteriostatic, antiviral, antimalarial, antipyretic and analgesic properties (Amin et al., 2019) . Currently, the pleiotropic actions of metformin in humans have been extensively documented, spanning from its well-established role in T2D treatment to cardio-and nephro-protection, as well as antiproliferative, antifbrotic, antioxidant, immune-modulatory and antiaging effects (Ursini et al., 2018) . Metformin has also been reported for its beneficial action on hepatitis C virus infections by ameliorating insulin resistance in the infected subjects (Tsai et al., 2017) .

We therefore further explored the potential mechanisms underlying the paradox of metformin treatment is associated with increased acidosis but not mortality in individuals with COVID-19 and J o u r n a l P r e -p r o o f pre-existing T2D by delineating the dynamic profiles of indicators of cardiac injury and heart failure and inflammatory factors. Some indicators without uniform normal ranges among different sites were normalized with the corresponding upper limits of normal ranges (ULNs) according to the specific criteria set in each hospital (Table S12) . These parameters were tracked from day 1 after admission to day 28 and plotted by using a locally weighted scatterplot smoothing (Loess) model (Figure 2) . We found that the indicators for cardiac injury (CK-MB) and heart failure (B type natriuretic peptide [BNP] and N terminal pro BNP [NTproBNP]) were consistently and markedly lower in the metformin group compared to the non-metformin group during the 28-day observation period (Figure 2A and 2B) .

Subgroup analysis showed that the reduction of these indicators was more evident in individuals with severe COVID-19. Metformin users also had a lower level of neutrophil counts, but a higher level of lymphocyte counts in the blood, particularly in individuals with severe COVID-19 status, compated to the nonsuers ( Figure 3A and 3B). Meanwhile, the dynamic trajectories of serum inflammatory factors, including CRP, interleukin-6 (IL-6), interleukin-2 (IL-2) and tumor necrosis factor-alpha (TNF-α), all showed lower degrees of elevation in the metformin group than the non-metformin group, particularly in the subgroup of individuals with severe COVID-19 ( Figure 3C-3F ).

This result is in good agreement with numerous previous reports demonstrating that metformin can modulate the immune response and restore immune homeostasis in T cells, B cells, monocytes and macrophages and neutrophils via AMPK-dependent mechanisms (Pollak, 2017; Tomczynska et al., 2016; Ursini et al., 2018) . The immune-modulatory property of metformin may also partially account for the cardioprotective function in addition to its impact on metabolic activity and energy utilization (Cameron et al., 2016; Tzanavari et al., 2016) . Extensive studies have demonstrated that metformin can improve myocardial energy homeostasis by activating the AMPK pathway and improving lipid and glucose utilization in failing hearts (Dziubak et al., 2018) . Indeed, the association of metformin use and reduced incidences of heart failure in the COVID-19 individuals with pre-existing T2D was consistently demonstrated by both the Cox regression model with time-varying exposure and mixed-effect Cox regression model following PSM.

The potential effect of metformin on ACE2 expression may also offer additional protection against COVID-19. Metformin activates AMPK, which phosphorylates ACE2 protein on its Ser-680 residue, and decreases its ubiquitination and degradation (Zhang et al., 2018a) . The protective function of ACE2 on the cardiopulmonary system has been well established (Imai et al., 2005; Monteil et al., 2020; Zhang et al., 2018a) . Meanwhile, post-translational modifications on ACE2 may also lead to conformation changes that diminish the binding of SARS-CoV-2 to the cell surface. Overall, these known potential beneficial effects of metformin may underlie the paradox that increased acidosis did not translate into higher mortality in metformin-treated individuals compared to individuals treated with other anti-diabetic drugs among individuals with COVID-19 and pre-existing T2D.

In conclusion, metformin use is associated with increased incidence of acidosis but not mortality in individuals with COVID-19 and pre-existing T2D. The association between metformin use and acidosis is significantly correlated with the high dose of metformin, lower kidney function and severity of COVID-19. Our findings provide clinical evidence in support of continuing metformin use in individuals with COVID-19 and pre-existing T2D, but such patients with severe COVID-19

should be monitored closely for the development of lactic acidosis, acidosis and decreased kidney function. Our findings also suggest that the dose of metformin administration might be critical to avoid the development of acidosis, while metformin use inindividuals with impaired kidney function should be careful considered in the setting of COVID-19.

This retrospective study has several limitations. Firstly, all data were collected from the individuals admitted in hospitals in Hubei Province, China. Hence, the impact of metformin use on the prognosis of COVID-19 individuals with pre-existing T2D might be different in the outpatient setting or geographically or ethnically diverse cohorts. Secondly, the pre-hospitalization medication was not available under the urgent circumstance of COVID-19 pandemic. Therefore, the impact of prehospital medications on the outcomes of the individuals could not be analyzed. Thirdly, higher baseline blood glucose in the metformin group may have a confounding effect in analyzing the association between metformin use and clinical outcomes. However, we adjusted for the baseline blood glucose concentration as well as other confounding variables in the Cox regression model with time-varying exposure and balanced the difference in blood glucose along with other major confounding variables by applying PSM before the Mixed-effect Cox analysis. These integrated analyzing strategies should maximally, although not completely, abolish the confounding effect of blood glucose in analyzing the association between metformin use and clinical outcomes. Fourthly, due to the retrospective nature of the study, we could not determine the definitive causal effect between metformin use and the outcomes of the individuals in this study. Rather, randomized prospective studies will be needed in geographically and ethnically diverse cohorts to confirm the association between metformin use and the progression of COVID-19 in individuals with pre-existing T2D.

J o u r n a l P r e -p r o o f STAR METHODS

Requests for additional information, resources and reagents should be directed to the Lead Contact, Hongliang Li (lihl@whu.edu.cn).

No new reagents or materials were generated in this study.

Data related to this study is available from the lead corresponding author upon request. An email address will be provided for communicating with the research team once data sharing is approved.

The request should include a proposal containing detailed aims, study plan, and other information and materials. It will be evaluated to ensure the scientific rationality of the request and the security of the data. The data related any specific patient can be shared only after internal review and approval of the submitted proposal and any related requested materials by an institutional committee. Under no circumstances will information and data with patient names and other identifiers will be shared.

This retrospective cohort study was multi-centered and the study subjects included individuals with confirmed COVID-19 admitted to 16 hospitals from Hubei, China, between December 30 th , 2019

and April 13 th , 2020. The final date of follow up was April 16 th , 2020. The study design and protocol were approved by the Institutional Ethics Committee of the central Institution as well as each of the institutional ethics boards of the participating hospitals. As this retrospective study only involved analysis of existing data without alteration of individuals' intervention or welfare, the informed consent was waived by the ethics boards of the hospitals.

There were 2,563 individuals diagnosed with T2D out of 15,451 individuals with confirmed COVID-19. Individuals who were younger than 18 or older than 80 years or had incomplete medical records (e.g., transfer to any other hospital), or death from other acute lethal conditions (e.g., acute myocardial infarction, acute coronary syndrome, acute pulmonary embolism, or acute stroke), decompensated or end-stage of chronic organ dysfunctions (e.g., decompensated cirrhosis, J o u r n a l P r e -p r o o f decompensated chronic renal insufficiency or eGFR less than 30 ml/min/1.73 m 2 ), pregnancy, prehospital ketoacidosis or hyperosmolar coma were excluded. Finally, there were 1,213 individuals entered statistical analysis.

The medical records from the participating cohort were processed and analyzed by a highly integrated research team composed of physicians, data scientists and statisticians, after deidentification to remove and replace all personal information (e.g., name and ID) of the participants using a coding system. All information related to the baseline characteristics, epidemiological records, symptoms, clinical manifestations, radiographic features from CT, laboratory findings, treatments, life-supporting interventions and clinical outcomes during the hospitalization were collected. The laboratory data included a routine blood test, fasting blood glucose, 2-hour postprandial blood glucose (2hPG), procalcitonin, CRP, D-dimer, lipid profiles, arterial blood gas analysis, serum electrolytes, serum indicators for acidosis, cardiac injury, liver injury, and kidney injury as well as serum inflammation mediators including IL-2, IL-6 and TNF-a.

The heterogeneity in the clinical data from different hospitals was further systemically streamlined, mined and analysed. All data were reviewed, interpreted and double-checked by the experienced physician team to guarantee the accuracy. T (cTNT), or high sensitivity cTNI (hs-cTNI), were above the upper limit of normal (ULN) Yancy et al., 2017) . Acute kidney injury was defined if the value of the serum creatinine level became ≥ 26.5 µmmol/L in 48 hours (Kellum et al., 2012) . DIC was defined according to the criteria of the International Society on Thrombosis and Hemostasis (ISTH) (Gando et al., 2013) .

Metabolic acidosis was defined as a blood pH ＜ 7.35 and a decrease in plasma bicarbonate concentration (HCO3 − ) < 22 mmol/L (Kraut and Madias, 2010) . Lactic acidosis was defined as acidosis (PH<7.35) and Lactate levels > 5 mmol/L (Lalau, 2010) (Lexis et al., 2014) . Heart failure was defined when serum BNP or NTProBNP were above the ULNs according to 2017 ACC/AHA/HFSA Guideline for the Management of Heart Failure (Yancy et al., 2017) . The primary endpoint of the study was 28-day all-cause death. The secondary endpoints included the occurrences of lactic acidosis, acidosis, ARDS, acute cardiac injury, acute kidney injury, heart failure, or DIC.

In current study, two independent statistical models were used to evaluate the association of metformin exposure and outcomes including 28-day mortality, lactic acidosis, acidosis, ARDS, acute cardiac injury, acute kidney injury, heart failure or DIC. One approach was Cox proportional hazards regression model based on the entire cohorts accounting for time-varying exposure that adjusted for baseline differences and accounted for immortal time bias (metformin therapy as a time-varying exposure); The other model was mixed effect Cox proportional hazards regression model after PSM for baseline characteristics, but without considering immortal time bias. The hospital site was considered as a random effect in the mixed-effect Cox model.

Metformin therapy may be delayed or discontinued in individuals with progressive conditions. The primary and secondary outcomes occurred before the use of metformin should not be considered as the endpoints associated with metformin application (Stricker and Stijnen, 2010) . Therefore, we introduced Cox proportional hazards regression model with time-varying exposure using samples in the entire cohorts in the analysis. Based on the medication histories, metformin exposure status was defined every day during the follow-up until the outcomes (i.e. mortality, lactic acidosis, acidosis, ARDS, acute cardiac injury, acute kidney injury, heart failure or DIC) appeared. This strategy allowed us to determine the time from hospital admission to initiation of metformin and the time from stopping metformin administration to appearing of the outcomes, which contributed to the untreated follow-up time in statistical analysis (Bowker et al., 2010; Shirani et al., 2012) . In each event time, there was a risk set that contains all cohort members under observation with an exposure status (exposed or unexposed). Besides, potential confounding variables at baseline were adjusted, J o u r n a l P r e -p r o o f which included pre-existing coronary heart disease and cerebrovascular disease, increase of CRP, ALT and serum creatine levels, blood glucose, and eGFR. Identical confounders were adjusted when analyzing the association of metformin therapy and clinical outcomes in the full T2D cohort, mild cohort and severe cohort. Adjusted hazard ratios (aHRs) with 95% confidence intervals were calculated. Schoenfeld's global test was performed to validate the validity of the models (Zhang et al., 2018b) .

Sensitivity analyses were conducted related to the Cox regression model with time-varying exposure. 

The PSM method was applied to balance the variables potentially confounding the association between metformin use and the outcomes in the study cohort (Waljee et al., 2013) . The PSM cohorts were identified by balancing the age, sex, fever and dyspnea, vital signs (heart rate, breath and blood pressure), SpO2 < 95, CT lesion, increase of neutrophils, blood glucose, increase of CRP, decrease of lymphocytes, kidney function (i.e., eGFR), proportion of insulin usage, indicators of liver injury (i.e., elevation of ALT) and heart injury (i.e. elevation of cTNI). The comorbidities (hypertension, coronary artery disease, cerebrovascular disease, chronic liver disease, chronic kidney disease and heart failure on admission) were also balanced in the matched Metformin and non-Metformin cohorts. The propensity score was estimated using multivariable logistic regression model to predict the probability of Metformin use contributed by the above variables. The logistic regression model was diagnosed by inspecting influential values and calculating multicollinearity. The matching ratio was at 1:1 for the Metformin group vs. the non-Metformin group. For all matching pairs, a caliper size of 0.05 was applied according to the propensity scores. The balance between covariates was evaluated by estimating the standardized differences before and after matching. Only those with absolute value < 0.1 were considered as qualified matching.

The Mixed-effect Cox model based on PSM cohorts was used to analyze the risk for composite endpoints. Residual imbalanced variates were further adjusted in the mixed effect Cox proportional hazards regression model. The incidence of increased creatine, AST, CRP, urea and decrease in RBC count were the remaining difference in the Metformin group and non-Metformin group in all T2D individuals; The incidence of increased creatine and urea were post-PSM difference in the Metformin group and non-metformin group in the mild individuals; and, in the severe cases, we further adjusted incidence of increased AST, CRP, urea, creatine kinase (CK), procalcitonin and decrease in RBC count, platelet count and eGFR. The hospital site was considered as a random effect in the mixed-effect Cox model. Furthermore, Harrell's concordance indexes (C-indexes) were calculated to evaluate the prediction capability of the mixed-effect Cox model (Harrell et al., 1982) . Two sensitivity analyses were performed to evaluate the robustness of propensity score-matched cohort analyses. In the first sensitivity analysis, the optimal caliper was set to 0.04, while in the second sensitivity analysis cerebrovascular disease was not included in matching.

A binary logistic regression model was applied to evaluate the association of baseline characteristics (age, gender, neutrophil to lymphocyte ratio, AST, eGFR, procalcitonin, SpO2<93%, pre-existing chronic obstructive pulmonary disease (COPD), coronary heart disease and cerebrovascular disease and use of ACE inhibitors (ACEI) or angiotensin receptor blockers (ARBs) or the dose of metformin used before lactic acidosis or metabolic acidosis with the lactic acidosis or metabolic acidosis in the longitudinal cohort. The parallel lines assumption of the model was also tested and met. The P values were 2-sided, and an alpha level of 0.05 was used to define statistical significance.

R-3.6.3 (R Foundation for Statistical Computing, Vienna, Austria) and SPSS Statistics (version 23.0, IBM, Armonk, NY, USA) software were used to perform all statistical analysis. Data were presented as median and interquartile range (IQR) for continuous variables or as frequency rates and percentage (%) for categorical variables. Student's t-tests (normally distributed) or Mann-Whitney U test (nonnormally distributed) were used for comparison of continuous variables between 2 groups.

Fisher's exact test or χ2 test were used to analyze the comparison of categorical variables. Dynamic changes of factors related to acute cardiac injury, immunoregulation and inflammation in the metformin and non-metformin groups from day 1 to day 28 after admission were depicted using locally weighted scatterplot smoothing (LOESS) model. Statistical difference was accepted only if a difference with a two-side α was less than 0.05. 

We have no competing interests to declare. 8.6(6.5-12.5) 9.0(6.7-13.1) 8.3(6.4-11.8) 0.197 0.001 Abbreviation: SBP, systolic blood pressure; DBP, Diastolic blood pressure; SpO2,oxygen saturation; RBC, red blood cells; ALT, alanine aminotransferase; eGFR, estimated glomerular filtration rate; LDL-c, low density lipoprotein cholesterol; IQR, interquartile range; SD, standardized difference. a Upper limit of normal (ULN) was defined according to criteria in each hospital. b Individuals with T2D taking metformin during hospitalization were enrolled in the metformin cohort. Individuals discontinued treatment of diabetes due to inability to take medications or diabetes were not excluded from the cohort. c Individuals with T2D who never took metformin during hospitalization were enrolled in the non-metformin cohort. d SD, Standardized differences were used to compare the means of baseline covariates between metformin and non-metformin groups. e P values were calculated by Mann-Whitney U test for non-normally distributed continuous variables and Fisher's exact test or χ2 test for categorical variables.

J o u r n a l P r e -p r o o f metformin and non-metformin cohorts included age, gender, comorbidities (cerebrovascular disease, coronary heart disease), blood glucose, C-reactive protein, estimated glomerular filtration rate, alanine aminotransferase and Creatinine. b The P values were calculated based on Time varying-Cox model. c In the Mixed-effect Cox proportional hazard model, adjusted variables for comparison between metformin and non-metformin cohorts included age, gender, C-reactive protein, aspartate aminotransferase, urea, red blood cell, creatinine and hospital site as a random effect. d The P values were calculated based on Mixed-effect Cox proportional hazard model. metformin and non-metformin cohorts included age, gender, comorbidities (cerebrovascular disease, coronary heart disease), blood glucose, C-reactive protein, estimated glomerular filtration rate, alanine aminotransferase and Creatinine. b The P values were calculated based on Time varying-Cox model. c In the Mixed-effect Cox proportional hazard model, adjusted variables for comparison between metformin and non-metformin cohorts included age, gender, C-reactive protein, aspartate aminotransferase, urea, red blood cell, creatinine and hospital site as a random effect. Table s2 Baseline characteristic in individuals of metformin and non-metformin groups after PSM, related to Table 2 

Chronic obstructive pulmonary disease, n(%) 7(0.8%) 3(0.6%) 4(0.9%) -0.025

Heart failure, n(%) 0(0.0%) 0(0.0%) 0(0.0%) 0.000 1(0.2%) 4(0.9%) -0.087 0.374 a Individuals with T2D taking metformin during hospitalization were enrolled in the metformin cohort. Individuals discontinued treatment of diabetes due to inability to take medications or diabetes were not excluded from the cohort. b Individuals with T2D who never took metformin during hospitalization were enrolled in the non-metformin cohort. c SD, Standardized differences were used to compare the means of baseline covariates between metformin and non-metformin group. d The P values were calculated by Fisher's exact test or χ2 test. 

Acidosis 0(0%) 0(0%) 0(0%) 1.000

Lactates Acidosis 0(0%) 0(0%) 0(0%) 1.000 a Individuals with T2D taking metformin during hospitalization were enrolled in the metformin cohort. Individuals discontinued treatment of diabetes due to inability to take medications or diabetes were not excluded from the cohort.

b Individuals with T2D who never took metformin during hospitalization were enrolled in the non-metformin cohort. 

Chronic obstructive pulmonary disease, n(%) 2(0.6%) 1(0.4%) 1.000 3(0.9%) 3(1.1%) 1.000

Heart failure, n(%) 0(0.0%) 0(0.0%) 1.000 0(0.0%) 2(0.7%) 0 (cerebrovascular disease, coronary heart disease), blood glucose, C-reactive protein, estimated glomerular filtration rate, alanine aminotransferase and Creatinine. b The P values were calculated based on Cox model-Time varying hazard model. c In the Mixed-effect Cox proportional hazard model, adjusted variables for comparison between metformin and non-metformin cohorts included age, gender, C-reactive protein, aspartate aminotransferase, urea, red blood cell, creatinine and hospital site as a random effect. d The P values were calculated based on Mixed-effect Cox proportional hazard model.

Chronic obstructive pulmonary disease, n(%) 1(0.5%) 1(0.5%) 0.000 2(0.9%) 3(1.3%) -0.042

Heart failure, n(%) 0(0.0%) 0(0.0%) 0.000 0(0.0%) 0(0.0%) 0.000

Coronary heart disease, n(%) 25(11.7%) 29(13.6%) -0.056 32(13.9%) 36(15.7%) -0.049 Cerebrovascular diseases, n(%) 6(2.8%) 5(2.4%) 0.030 9(3.9%) 9(3.9%) 0.000

Chronic liver disease, n(%) 3(1.4%) 5(2.4%) -0.069 6(2.6%) 4(1.7%) 0.060

Chronic renal diseases, n(%) 4(1.9%) 4(1.9%) 0.000 6(2.6%) 7(3.0%) -0.026

Unilateral lesion, n(%) 13(6.7%) 9(4.4%) 0.103 11 ( Invasive ventilation, n(%) 0(0.0%) 0(0.0%) 0.000 9(3.9%) 11(4.8%) -0.043

Renal replacement therapy, n(%) 0(0.0%) 0(0.0%) 0.000 1(0.4%) 4(1.7%) -0.126

Extracorporeal membrane oxygenation, n(%) 0(0.0%) 0(0.0%) 0.000 2(0.9%) 4(1.8%) -0.074

Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2019

The journey of metformin from glycaemic control to mTOR inhibition and the suppression of tumour growth

Metformin: historical overview

Blood lactate levels are superior to oxygen-derived variables in predicting outcome in human septic shock

Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: a nested case-control analysis

Practical recommendations for the management of diabetes in patients with COVID-19

Glucose-lowering agents and cancer mortality rates in type 2 diabetes: assessing effects of time-varying exposure

Anti-Inflammatory Effects of Metformin Irrespective of Diabetes Status

Guidelines for the prevention and control of type 2 diabetes in China

Lactic acidosis and severe septic shock in metformin users: a cohort study

Metabolic Effects of Metformin in the Failing Heart. International journal of molecular sciences 19

Metformin: from mechanisms of action to therapies

Scientific, Standardization Committee on

Differentiating disseminated intravascular coagulation (DIC) with the fibrinolytic phenotype from coagulopathy of trauma and acute coagulopathy of trauma-shock (COT/ACOTS)

Evaluating the yield of medical tests

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Angiotensin-converting enzyme 2 protects from severe acute lung failure

Metformin in patients with type 2 diabetes and kidney disease: a systematic review

Kidney disease: Improving global outcomes (KDIGO) acute kidney injury work group. KDIGO clinical practice guideline for acute kidney injury

Metabolic acidosis: pathophysiology, diagnosis and management

Lactic acidosis induced by metformin: incidence, management and prevention

Effect of metformin on left ventricular function after acute myocardial infarction in patients without diabetes: the GIPS-III randomized clinical trial

Neutrophil-to-lymphocyte ratio predicts critical illness patients with 2019 coronavirus disease in the early stage

Metformin Treatment Was Associated with Decreased Mortality in COVID-19 Patients with Diabetes in a Retrospective Analysis

COVID-19: consider cytokine storm syndromes and immunosuppression

Serum lactate is associated with mortality in severe sepsis independent of organ failure and shock

Lactic acidosis in patients with diabetes treated with metformin

Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2

Prior metformin therapy and 30-day mortality in patients with acute respiratory distress syndrome: a nationwide cohort study

Type 2 Diabetes Mellitus Treatment Patterns Across Europe: A Population-based

The effects of metformin on gut microbiota and the immune system as research frontiers

The mechanisms of action of metformin

Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the

Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis

Analysis of individual drug use as a time-varying determinant of exposure in prospective population-based cohort studies

Lactic Acidosis in Sepsis: It's Not All Anaerobic: Implications for Diagnosis and Management

Metformin -The Drug for the Treatment of Autoimmune Diseases; A New Use of a Known Anti-Diabetic Drug

Metformin activates type I interferon signaling against HCV via activation of adenosine monophosphate

Metformin protects against infection-induced myocardial dysfunction

New Deal" of an Old Drug. Front Immunol 9

Comparison of imputation methods for missing laboratory data in medicine

Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected human cases Interim guidance. (World Health Organization )

2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America

AMP-activated Protein Kinase Phosphorylation of Angiotensin-Converting Enzyme 2 in Endothelium Mitigates Pulmonary Hypertension

Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19

Time-varying covariates and coefficients in Cox regression models

Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes

Lymphocyte count <1.1, 10^9/L

Blood glucose, median (IQR), mmol/L

Abbreviation: SBP, systolic blood pressure

Diastolic blood pressure

eGFR, estimated glomerular filtration rate; LDL-c, low density lipoprotein cholesterol

Individuals with T2D taking metformin during hospitalization were enrolled in the metformin cohort. Individuals discontinued treatment of diabetes due

Standardized differences were used to compare the means of baseline covariates between metformin and non-metformin groups

Blood glucose, median (IQR), mmol/L

Abbreviation: SBP, systolic blood pressure

Diastolic blood pressure

red blood cells; CRP, C-reactive protein

ALT, alanine aminotransferase; eGFR, estimated glomerular filtration rate

P values were calculated by Mann-Whitney U test for non-normally distributed continuous variables and Fisher's exact test or 2 test for categorical variables

DBP, median(IQR), mmHg

Blood glucose, median (IQR)

Abbreviation: SBP, systolic blood pressure

Diastolic blood pressure

ALT, alanine aminotransferase; eGFR, estimated glomerular filtration rate; LDL-c, low density lipoprotein cholesterol

Standardized differences were used to compare the means of baseline covariates between metformin and non-metformin groups

a Individuals with T2D taking metformin during hospitalization were enrolled in the metformin cohort. Individuals discontinued treatment of diabetes due to inability to take medications or diabetes were not excluded from the cohort. b Individuals with T2D who never took metformin during hospitalization were enrolled in the non-metformin cohort. c SD, Standardized differences were used to compare the means of baseline covariates between metformin and non-metformin groups. show that metformin use is significantly associated with higher incidence of acidosis, particularly in cases with severe COVID-19, but not with 28-day all-cause mortality. They also found that metformin use is significantly associated with reduced heart failure and inflammation.

A retrospective study of 1,213 patients on metformin with COVID-19 was performed Metformin was associated with increased incidence of acidosis in such patientsMetformin was not associated with increased 28-day all-cause mortality in the patients Metformin was significantly associated with reduced heart failure and inflammation